Monthly Archives: September 2016

Contract Documents Provide The Answers To Numerous Questions About A Prospective Partner’s Flexibility On A Wide Range Of Important Issues, Many Of Which Will Have A Significant Impact On Each Party’s Ability To Derive Value From The Deal.

Diabetic retinopathy is a deterioration of the blood vessels in the retina that usually affects both eyes. Diabetes causes damage to the blood vessels that nourish the retina, the seeing part of the eye. For decades, PDP has been treated with scatter laser surgery, sometimes called pan retinal laser surgery or pan retinal photo coagulation. People with severe non proliferative diabetic retinopathy have a high risk of developing PDP and may need a comprehensive dilated eye exam as often as every 2 to 4 months. These are anti-VEGF Vascular Endothelial Growth Factor drugs and they target the substance in the body which is responsible for the development of blood vessels. Once the retinopathy has reached this stage it will be treated with laser therapy. no dataThe disease often progresses unnoticed until it affects vision. However, they are weak and often burst, causing bleeding in the eye.

This data driven report contains multiple links to online copies of actual bladder cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. http://ellamasonvoice.sunshineboysquartet.com/2016/08/29/the-best-direction-for-wise-plans-of-eye-bags/The initial chapters of this report provide an orientation of partnering trends. Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company. Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand. Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record. Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest. Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/global-retinopathy-partnering-2010-to-2016-300317445.html

After Light Passes Through The Cornea, It Travels Through A Space Called The Anterior Chamber Which Is Filled With A Protective Fluid Called The Aqueous Humour, Through The Pupil Which Is A Hole In The Iris, The Coloured Part Of The Eye, And Then Through A Lens That Performs More Focusing.

The.etina of a person with diabetic retinopathy and DBE, as viewed by optical coherence tomography OCR. It can also help you lose weight, especially when you exercise, too. Topics For Consideration With Fundamental Criteria For Eye BagsPDP affects vision in the following ways: Vitreous haemorrhage: delicate new blood vessels bleed into the vitreous — the gel in the canter of the eye — preventing light rays from reaching the retina. Deteriorating blood vessels can become blocked or deformed. Exposure to the sun or looking at the sun during an eclipse can cause damage solar retinopathy, as well as certain drugs for example, chloroquine, thioridazine, and large doses of tamoxifen.  Small areas of balloon-like swelling in the retina’s tiny blood vessels, called micro aneurysms, occur at this earliest stage of the disease. After light passes through the cornea, it travels through a space called the anterior chamber which is filled with a protective fluid called the aqueous humour, through the pupil which is a hole in the iris, the coloured part of the eye, and then through a lens that performs more focusing. Fortunately, with regular, proper eye care and treatment when necessary, the incidence of severe vision loss has been greatly reduced. In later stages of retinopathy, serious complications can result, including retinal detachment and blindness . This condition is the leading cause of blindness in people between the ages of 20 and 60. Follow your eye doctor’s advice on how to protect your vision. Retinopathy is a “silent” disease of the back of the eye – it has no symptoms during its early stage.  Tests you may have involved: Measuring the fluid pressure inside your eyes tonometry Checking the structures inside your eyes slit lamp exam Checking and photographing your retinas fluoresce in angiography If you have the early stage of diabetic retinopathy non proliferative, the eye doctor may see: Blood vessels in the eye that are larger in certain spots called micro aneurysms Blood vessels that are blocked Small amounts of bleeding retinal haemorrhages and fluid leaking into the retina If you have advanced retinopathy proliferative, the eye doctor may see: New blood vessels starting to grow in the eye that are weak and can bleed Small scars forming on the retina and in other parts of the eye the vitreous This exam is different from going to the eye doctor optometrist to have your vision checked and to see whether you need new glasses. The retina detects light and converts it to signals sent through the optic nerve to the brain.

Gardner, M.D., M.S., studies the effects of diabetes on the retina. Laser treatments may also be used. Incidence; Causes and Development Diabetic retinopathy is the leading cause of blindness in people ages 20 to 74.  The macula is the most used area of the retina. Control your blood sugar glucose level by: Checking your blood sugar as often as instructed by your diabetes health care provider and keeping a record of your numbers so you know the types of foods and activities that affect your blood sugar level Taking medicine or insulin as instructed Treatments can reduce vision loss. People with this disease frequently have no symptoms in the early stages. There are several treatments for glaucoma. Doppler optical coherence tomography.

Adult Skin Problems Slideshow FRIDAY, Aug. 19, 2016 (HealthDay News) — Steroids used to help premature babies ‘ lungs work may increase their risk of eye problems , a new study suggests. no dataDoctors often give corticosteroids to babies whose birth weight is very low to improve lung function, but it’s long been suspected that the drugs may have harmful side effects. “Clinicians need to use their best judgment to balance the positive effects from steroids on developing lungs with potential negative effects on developing eyes in very premature infants,” said lead investigator Dr. Tammy Movsas. For the new study, the researchers analyzed data from nearly 1,500 infants who weighed less than 500 grams (1.1 pounds) at birth. Although the study couldn’t prove cause-and-effect, the risk of an eye condition called retinopathy of prematurity (ROP) was 60 percent higher for babies treated with steroids, the researchers found. And babies’ risk of developing an advanced case of ROP was 70 percent higher if they were on the drugs, the findings showed. Movsas called the increased ROP risk modest, but significant. The study was published recently in the Journal of the American Association for Pediatric Ophthalmology and Strabismus. “This study has potential clinical significance since children with a history of ROP are not only at increased risk for visual impairments from the ROP itself, but are also at increased risk for developing other ocular disorders later in life,” Movsas said in a journal news release.

For the original version including any supplementary images or video, visit http://www.medicinenet.com/script/main/art.asp?articlekey=197766

We Are Continuing To Conduct Preclinical Studies With Multiple 3ga Candidates In House And With Our Collaborators, With A Goal Of Advancing This Technology To Clinical Development.

People who have these conditions may be more prone to get uveitis: In some cases, doctors don’t know what causes non-infectious uveitis. After graduating from St. Your doctor may prescribe either eye drops or pills. There he was involved in research in radiation biology and received the husking Scholarship. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Genes can play an important role in uveitis. This injury, or trauma, may be caused by a blow or wound, eye surgery, a disease such as a virus, bacteria infection, or a parasite. Severe inflammation takes longer to clear up than mild inflammation does. Your doctor may order blood tests, X-rays, or other lab tests to check for medical conditions that might be linked with uveitis. http://www.theactproject.com/advisingeyesurgeon/2016/08/29/the-best-routes-for-speedy-plans-in-laser-eye-surgery/The disorder may affect only one eye.

This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. Phil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets. About Ideras Third Generation Antisense Platform (3GA) Ideras proprietary third-generation antisense (3GA) platform technology is focused on silencing the mRNA associated with disease causing genes. Idera has designed 3GA oligonucleotides to overcome specific challenges associated with earlier generation antisense technologies and RNAi technologies. About Idera Pharmaceuticals, Inc. no dataIdera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Ideras proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html

Viruses.an Be Treated With Antiviral Medication, Bacterial Infections Can Be Treated With  Antibiotics, And Fungal Infections Can Be Treated With Anti Fungal Medication .

and EXTON, Pa., Aug. 24, 2016 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. ( IDRA ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform. In the presentation, entitled Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides, Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the region similar to that observed with siRNA. These excision products are different from those observed with earlier generations of antisense. This presentation also provided a demonstration of 3GAs specificity by showing that the incorporation of a mismatch at the region of excision led to the loss of gene-silencing activity. Based on these studies, the company is also conducting studies to further the potential applications of 3GAs in targeting diseases caused by point mutations. Data from these studies is expected to be presented in the second half of 2016. This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. http://www.alabamascholars.org/newgabrielprice/2016/09/13/astute-programs-in-glaucoma-simplified/Phil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html

The doctor may dilate your eyes or use a special dye to make certain parts easier to see. Some Useful Guidance On Recognising Aspects Of Eye Bags | New Scarlett BurnsOther than avoiding certain infections, including syphilis or HIV, there is no way to prevent uveitis. Smith BR, Spurrier DJ, Martin GT, Rosenbaum GT. If your uveitis was caused by another medical condition, you’ll need to make sure you’re getting the right treatment for it as well. Review. The dye only temporarily stains the eye. Upon entry to the eye, these cells may be returned to an inducible Greg state by the presence of IL-10 and TGF-beta from microglia. A recent NEI-funded study, called the Multicenter Uveitis Treatment Trial MUST, compared the safety and effectiveness of conventional treatment for these forms of uveitis, which suppresses a patient’s entire immune system, with a new local treatment that exclusively suppressed inflammation in the affected eye. She currently practices at One to One Eye Care in San Diego, A. The inflammation can also damage delicate cells on the cornea and retina, causing fluid build-up that blurs and damages the vision, sometimes irreversibly. If the retina is also involved, it is called chorioretinitis. Treatment for uveitis will depend on which areas of the eye are affected and what caused the condition. Some types of anterior uveitis can be chronic or recurrent. She is a fellow of the American Academy of Ophthalmology.

Viruses.an be treated with antiviral medication, bacterial infections can be treated with  antibiotics, and fungal infections can be treated with anti fungal medication . So it is important to follow your doctor’s dosage instructions carefully and to keep visiting him or her regularly to monitor the progress of the treatment. Newton, MA: Integrative Medicine Communications; 2000:18;165-166. A Funduscopic Exam: The pupil is widened dilated with eye drops and then a light is shown through with an instrument called an ophthalmoscope to noninvasively inspect the back, inside part of the eye. Herpes Foster eye complications: rates and trends. If the biliary body is also involved, it is called iridocyclitis. The retina is a layer of cells in the back of the eye. These drops dilate your pupils and relieve pain by relaxing the muscles in your eye. If the urea is inflamed in the middle or intermediate region of the eye, it is called pars planitis or intermediate uveitis. In many cases, perhaps as many as a third or half of all uveitis cases, the cause of the inflammation is not known.

Antibiotic Drops Help Prevent A Secondary Bacterial Infection.

For.ed, swollen eyes with pus-like discharge and splintering pains. Apply a thin layer of potato peels over the eyelids. Such infants should be treated with a two-week course of systemic erythromycin. 12 Adult inclusion conjunctivitis typically presents in young, sexually active persons between 18 and 30 years of age. http://experteyedoc.sunshineboysquartet.com/2016/09/13/tips-for-picking-factors-for-glaucoma/It is an inflammation of the conjunctiva, the thin, clear tissue that lines the inside of the eyelid and the white part of the eyeball. Antibiotic drops help prevent a secondary bacterial infection. http://charlesriveratravel.bandonseaview.com/2016/08/29/some-updated-ideas-on-central-aspects-of-astigmatism/Wear eyeglasses instead of contact lenses . Sebaceous cell carcinoma that is invading the conjunctiva and the superficial cornea. Other facial clues to the aetiology of conjunctivitis include the presence of herpes labials or a dermatomal vesicular eruption suggestive of shingles. Manage simple conjunctivitis in the ED. Throw away any make-up used while infected. Various topical agents, including trifluridine Viroptic, may be helpful.